CA
NZ
UK
AU
IND
US
…
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Biodesix, Inc. is a clinical diagnostics company that develops blood-based proteomic and molecular tests for lung disease and cancer, including the VeriStrat test for non-small cell lung cancer. Long-term growth may be supported by wider adoption of non-invasive diagnostics, expanding lung cancer screening and biopharma partnerships, while investors may find exposure to recurring testing revenue and data-driven tests attractive.
Primary risks include reliance on reimbursement and clinical adoption, competitive pressure from other liquid-biopsy and diagnostic providers, regulatory and validation hurdles, and revenue concentration in a limited test portfolio.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -35.27M | -42.93M | -52.15M | -65.45M | -43.16M |
| Net income | -35.27M | -42.93M | -52.15M | -80.39M | -44.48M |
| Selling general administrative | 87.55M | 80.45M | 67.76M | 61.46M | 50.52M |
| Selling and marketing expenses | - | - | - | 61.46M | 50.52M |
| Gross profit | 66.59M | 55.75M | 36.08M | 24.06M | 23.99M |
| Reconciled depreciation | 5.60M | 5.46M | 5.85M | 5.84M | 3.18M |
| Ebit | -27.55M | -34.67M | -42.61M | -50.51M | -39.32M |
| Ebitda | -21.88M | -29.22M | -37.10M | -50.40M | -39.33M |
| Depreciation and amortization | 5.67M | 5.46M | 5.51M | 0.11M | -0.01M |
| Operating income | -27.87M | -34.50M | -41.34M | -50.51M | -39.32M |
| Other operating expenses | 116.37M | 105.82M | 90.43M | 88.72M | 93.82M |
| Interest expense | 7.72M | 8.26M | 9.54M | 8.07M | 4.51M |
| Net interest income | -7.72M | -8.26M | -9.76M | -8.07M | -4.51M |
| Income tax expense | - | - | 5.34M | 14.94M | 1.32M |
| Total revenue | 88.50M | 71.32M | 49.09M | 38.21M | 54.51M |
| Total operating expenses | 94.36M | 90.25M | 77.42M | 74.56M | 63.31M |
| Cost of revenue | 21.91M | 15.57M | 13.01M | 14.15M | 30.52M |
| Total other income expense net | -7.39M | -8.43M | -10.80M | -14.94M | -3.84M |
| Net income from continuing ops | -35.27M | -42.93M | -63.34M | -65.45M | -43.16M |
| Net income applicable to common shares | - | - | - | -65.45M | -43.16M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 87.48M | 97.24M | 99.10M | 92.91M | 76.10M |
| Intangible assets | 3.88M | 5.87M | 7.91M | 9.80M | 11.62M |
| Other current assets | 4.50M | 4.64M | 4.22M | 5.18M | 7.25M |
| Total liab | 89.94M | 76.37M | 94.52M | 72.30M | 56.37M |
| Total stockholder equity | -2.46M | 20.88M | 4.58M | 20.61M | 19.73M |
| Deferred long term liab | - | - | - | 0.65M | - |
| Other current liab | 12.03M | 10.71M | 29.86M | 18.60M | 25.43M |
| Common stock | 0.01M | 0.14M | 0.10M | 0.08M | 0.03M |
| Capital stock | 0.01M | 0.14M | 0.10M | 0.08M | 0.03M |
| Retained earnings | -497.76M | -462.50M | -419.57M | -367.42M | -301.97M |
| Other liab | - | - | - | 19.20M | 17.42M |
| Good will | 15.03M | 15.03M | 15.03M | 15.03M | 15.03M |
| Other assets | - | - | - | 5.92M | 1.66M |
| Cash | 18.99M | 26.25M | 26.38M | 43.09M | 32.71M |
| Total current liabilities | 17.44M | 14.32M | 33.42M | 22.84M | 28.96M |
| Current deferred revenue | 0.96M | 0.68M | 0.32M | 0.96M | 1.85M |
| Net debt | 53.87M | 35.73M | 34.31M | -11.24M | -22.70M |
| Short term debt | 1.37M | 0.74M | 0.30M | 1.59M | 0.02M |
| Short long term debt | 0.01M | 0.02M | 0.05M | 0.05M | 0.02M |
| Short long term debt total | 72.85M | 61.98M | 60.69M | 31.85M | 10.01M |
| Other stockholder equity | 495.29M | 483.23M | 424.05M | 387.95M | 321.67M |
| Property plant equipment | - | - | - | 8.82M | 4.18M |
| Total current assets | 32.52M | 39.48M | 39.68M | 53.33M | 43.61M |
| Net tangible assets | - | - | - | -4.22M | -6.92M |
| Net receivables | 9.04M | 8.60M | 7.68M | 5.07M | 3.66M |
| Long term debt | 47.45M | 36.41M | 35.23M | 25.00M | 9.99M |
| Inventory | - | - | 1.40M | 1.40M | 2.90M |
| Accounts payable | 3.08M | 2.19M | 2.93M | 1.69M | 1.66M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | 8.23M | 7.26M | 6.86M | 5.92M | 1.66M |
| Non current assets total | 54.96M | 57.76M | 59.41M | 39.57M | 32.48M |
| Capital lease obligations | 25.40M | 25.55M | 25.41M | 6.80M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -3.44M | -22.05M | -3.53M | -2.55M |
| Change to liabilities | - | - | - | -1.99M | -9.11M |
| Total cashflows from investing activities | -0.40M | -3.44M | -23.06M | -3.53M | -2.55M |
| Net borrowings | 9.98M | -0.05M | 9.95M | 16.50M | -15.51M |
| Total cash from financing activities | 16.42M | 52.05M | 29.13M | 58.88M | 1.26M |
| Change to operating activities | - | - | - | -0.86M | 2.24M |
| Net income | -35.27M | -42.93M | -52.15M | -65.45M | -43.16M |
| Change in cash | -7.26M | -0.04M | -16.80M | 10.38M | -29.51M |
| Begin period cash flow | 26.33M | 26.37M | 43.17M | 32.80M | 62.31M |
| End period cash flow | 19.07M | 26.33M | 26.37M | 43.17M | 32.80M |
| Total cash from operating activities | -23.27M | -48.65M | -22.87M | -44.97M | -28.22M |
| Issuance of capital stock | 7.32M | 55.62M | 56.89M | 59.54M | 16.67M |
| Depreciation | 5.67M | 5.46M | 5.51M | 5.84M | 3.18M |
| Other cashflows from investing activities | -0.14M | -0.21M | -0.14M | - | - |
| Dividends paid | - | - | 0.64M | - | -0.33M |
| Change to inventory | 0.05M | 0.02M | 0.17M | 0.91M | 7.42M |
| Change to account receivables | -0.53M | -1.81M | -4.72M | -1.50M | 11.45M |
| Sale purchase of stock | 0.50M | 0.62M | 0.64M | 0.35M | 0.33M |
| Other cashflows from financing activities | -0.85M | -3.52M | -8.95M | 27.59M | 30.02M |
| Change to netincome | - | - | - | 18.98M | 7.17M |
| Capital expenditures | 0.26M | 3.23M | 23.06M | 3.53M | 2.55M |
| Change in working capital | 0.33M | -21.67M | 11.30M | -4.34M | 4.59M |
| Stock based compensation | 4.14M | 6.64M | 5.37M | 5.96M | 4.94M |
| Other non cash items | 1.85M | 3.86M | 7.09M | 13.01M | 4.33M |
| Free cash flow | -23.53M | -51.88M | -45.93M | -48.51M | -30.77M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BDSX Biodesix Inc |
0.08 0.38% |
21.26 | - | - | 1.47 | 44.57 | 2.11 | -2.72 |
| TMO Thermo Fisher Scientific Inc |
11.07 1.64% |
684.89 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
2.47 1.07% |
232.97 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
-1.44 5.45% |
24.98 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
1.07 4.51% |
24.78 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
919 West Dillon Road, Louisville, CO, United States, 80027
303 417 0500
334
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott Hutton | Pres, CEO & Director | 1972 |
| Ms. Robin Harper Cowie | CFO, Sec. & Treasurer | 1980 |
| Mr. Ryan H. Siurek | Chief Accounting Officer | 1972 |
| Dr. Heinrich Röder | Founder & CTO | NA |
| Dr. Robert W. Georgantas III, Ph.D. | Chief Scientific Officer | 1971 |
| Mr. Jeffrey A. Bojar | VP of Legal and Regulatory Affairs | NA |
| Mr. Matt Stauffer | VP of Sales | NA |
| Dr. Paul J. Beresford | Chief Bus. Officer | NA |
| Dr. Gary Anthony Pestano Ph.D. | Chief Devel. Officer | 1967 |
| Ms. Bobbi Coffin | Chief Growth Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.70%
Consumer Cyclical
-0.35%
Consumer Defensive
-0.54%
Energy
+0.40%
Financial Services
-0.54%
Financials
+0.30%
Healthcare
+0.19%
Industrials
+0.38%
Real Estate
+0.22%
Technology
+0.27%
Utilities
-0.53%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...